Recursion Pharmaceuticals (RXRX) reported mixed Q2 results, with revenue declining to $7.67 million and a narrowed net loss of $131.01 million. Key milestones include FDA clearance for a new trial and ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Infinity (Infinity Artificial Intelligence Institute), an early-stage AI infrastructure research company building the software layer that makes any AI chip inference-ready, today announced a new case ...